 |
SKDK and ICR handle Intra-Cellular Therapies as it is getting acquired by Johnson & Johnson for $14.6B.
J&J is offering $132 for each of the Intra-Cellular shares that trade on the NASDAQ.
The Financial Times reports the transaction is the biggest biotech deal since Pfizer acquired Seagen in 2023 for $46B.
Intra-Cellular works on treatments for central nervous system disorders—including major depressive disorder, generalized anxiety disorder and Parkinson’s disease.
Its Caplyta, a once-daily pill, is the only treatment that the Food & Drug Administration has approved to treat adults with schizophrenia and episodes associated with bipolar disorder depression.
About 2.4M adults live with schizophrenia, while 6.1M suffer from bipolar disorder.
Intra-Cellular CEO Sharon Mates said J&J ownership will enable her Bedminster, NJ-based company to reach even more patients around the world.
SKDK’s Erin Weinstein handles media for Intra-Cellular, while Juan Sanchez works Wall Street.
Interpublic posted a 5.1 percent drop in Q3 net revenues to $2.5B as CEO Philippe Krakowsky reports the final financial results of the publicly traded company.
Joele Frank handles Pine Gate Renewables as the Asheville, NC-based solar power development company declares Chapter 11 in the aftermath of Donald Trump’s cuts to wind & solar tax credits.
Stagwell CEO Mark Penn reports Q3 net revenues jumped 6 percent to $614.5M, a record performance for a non-political period. Operating income soared 45.7 percent to $60.9M.
Joele Frank works for Klöckner Pentaplast as the German maker of plastic films declares Chapter 11. A successful reorganization would slash its its corporate debt by $1.5B.
Teneo represents Metsera, the New York City biotech focused on weight-control products, which is subject to a bidding war between heavyweights Novo Nordisk and Pfizer.
